News
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback